Pick Pfizer's Rivals - TheStreet

This column was originally published on RealMoney on Feb. 8 at 9:25 a.m. EST. It's being republished as a bonus for TheStreet.com readers. For more information about subscribing to RealMoney, please click here.

Everybody wanted

Pfizer

(PFE) - Get Report

! They all wanted to know about Pfizer. I kid you not!

You know I always

play Lightning Round wherever I go. One guy will ask me about a stock in the airport, and no sooner do I answer than the next guy has a question and then the guy after that. Sure enough, there's a dozen questions, maybe two.

On

this trip to University of Virginia for the "Mad Money" Back to School Tour, every time we played I got asked about Pfizer -- maybe seven times. Again, I'm not kidding.

Perhaps because I had spent the afternoon with

Celgene

(CELG) - Get Report

COO Bob Hugin, in each case I shot back Celgene.

The comparison can't be lost on people. Think about it: Pfizer's been making its so-called "upside" surprises by firing people. Celgene's been making its

real

upside surprises by hiring people and selling more.

Pfizer's earnings could go down big in the out years as Lipitor comes off patent and nothing of any size replaces it. Celgene has 75 trials out there for Revlimid alone, its homegrown blood -cancer disease cure. Hugin says there are six other compounds coming that could also be huge. It's hard to believe that the earnings for this company won't be much bigger in six years, maybe much, much bigger.

But Pfizer has that yield and that brand name, and even though Celgene is a multi-billion dollar company, it's widely perceived as a one-trick nobody that can never take the Revlimid franchise much further than some international sales.

I believe that's wrong. More important, when you buy a drug stock you don't do it for the yield; the only reason Pfizer's yield is so large is because the stock has fallen so much.

I like

Gilead

(GILD) - Get Report

. It's now my biotech stock of the year, and it is on a torrid ramp.

I believe

Amgen's

(AMGN) - Get Report

cheap; so's

Genentech

(DNA)

.

Genzyme

(GENZ)

seems solid to me. And Celgene's done nothing since that last quarter.

All of these stocks on their

bad

days are better than Pfizer.

I wish my Lightning Round friends had heard me. But somehow I think that today, they still own Pfizer, and I have failed in my mission.

Random musings:

Look, you can see from this experience that you've got to get as many angles on a stock as possible. Here's one more tool to help:

TheStreet.com Ratings Screener. Use it to take a fresh look at the stocks you hold now (like Pfizer) or to find exactly the stock you're looking for.

At the time of publication, Cramer had no positions in any of the stocks mentioned in this post.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click

here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click

here to order his book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.